JSKN003 + capecitabine + oxaliplatin + enlonstobart

JSKN003 + capecitabine + oxaliplatin + enlonstobart is a combination regimen comprising an investigational anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003, the oral chemotherapeutic antimetabolite capecitabine (prodrug of 5-fluorouracil), the platinum-based chemotherapeutic agent oxaliplatin, and the investigational antibody enlonstobart. JSKN003 is engineered to target HER2 on tumor cells, subsequently releasing a topoisomerase I inhibitor payload via endocytosis to induce cytotoxicity, with improved serum stability and bystander effect. Capecitabine is converted in vivo to 5-fluorouracil, inhibiting DNA synthesis in rapidly dividing cancer cells, while oxaliplatin induces DNA crosslinks, inhibiting DNA replication and transcription. Enlonstobart is an investigational agent, presumed to be an antibody, for which mechanism and target are not yet fully characterized. This regimen is under investigation for treatment of advanced HER2-expressing solid tumors and platinum-resistant cancers, particularly in gastric, gastroesophageal junction, and ovarian cancers[1][2][3][5][7].